Navigation Links
Date Set for LightLab Damages Trial Against Volcano and Axsun
Date:2/9/2010

>Westford, MA is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab currently sells its OCT systems and imaging catheters in twenty countries in Europe, Asia, the Middle East and South America. It currently does not sell products in the United States for clinical use. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patient's wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more information, and more precise information, than ever before available. For more information, visit www.lightlabimaging.com.

SOURCE LightLab Imaging, Inc.

RELATED LINKS
http://www.lightlabimaging.com

'/>"/>

SOURCE LightLab Imaging, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
4. Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company
5. Delcath Systems Begins Data Analysis of Phase III Trial
6. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
9. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
10. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
11. Pivotal Trial Results for Motavizumab Published in Current Issue of Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... , CORALVILLE, Iowa, Dec. 16 ... Business Development agreement with Baker Consulting out of Walnut ... out of South Florida. Baker Consulting has been ... and assisting the company with its recently reported acquisition ...
... , SALT LAKE CITY, Dec. 16 ... "Company"), a medical device company engaged in the development and ... that Joe Pepper, PhD, has been appointed to the TechniScan ... "Joe has extensive experience running small to large medical devices ...
Cached Medicine Technology:Vivakor Signs Business Development Agreement With Baker Consulting 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... alleviate the suffering of shingles could move a step closer ... the go-ahead. A new shingles drug (FV-100), discovered ... of Pharmacy together with a virology group at the Rega ... due to complete Phase II of its clinical trials. ...
... ... 23, 2010 – Phybridge Inc. announced that it has joined the Cisco Developer Network ... has successfully completed interoperability testing with Cisco Unified Communications Manager, 7.1. , ... (PRWEB) March 23, 2010 -- ...
... ... survivors of the earthquake in Haiti. The Grand Canyon University community has donated more than ... on January 12, 2010. , ... Phoenix, AZ (PRWEB) March 23, 2010 -- Grand Canyon University,s Compassion and Generosity ...
... , COLLEYVILLE, Texas , March 23 E ... of the SS Choice No.7 STEALTH, which they originally designed for ... soldiers last summer and has been battle tested in Iraq ... comes in a matte black finish that is difficult to see ...
... , March 23 PSI Ambassador, actress and singer/songwriter ... and dozens of others who met with Members of Congress today ... which included a briefing to Congress, an attempt to form the ... Kerry , Congressman Jim McGovern and students from Oyster-Adams ...
... Yogi Bear’s ... pricing for the 2010 season! Plan an affordable and fun family vacation in North ... resort fees - just memories in the making at this family campground. , ... (PRWEB) March 23, 2010 -- Yogi ...
Cached Medicine News:Health News:Welsh shingles drug set for final hurdle 2Health News:Phybridge Inc. Joins the Cisco Developer Network and Completes Cisco Interoperability Verification Testing 2Health News:Grand Canyon University (GCU) Creates Special Relief Fund and Raises Money for Haiti Earthquake Survivors 2Health News:Combat E-Cigarette in Demand by Civilians 2Health News:Combat E-Cigarette in Demand by Civilians 3Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 2Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 3Health News:PSI Ambassador Mandy Moore Calls on Congress for Clean Water 4Health News:Announcing 2010 Stimulus Pricing on Adirondack Family Vacations 2Health News:Announcing 2010 Stimulus Pricing on Adirondack Family Vacations 3
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
Medicine Products: